Sonic Healthcare Interim Results For the Half-year ended 31 December 2006

Dr Colin Goldschmidt CEO and Managing Director

27 February 2007



Half-Year Summary

(1 July - 31 Dec 2006)

- Solid first half performance
 - Revenue up 12%
 - Net Profit up 12%
 - EPS up 8%
- Full-year guidance unchanged
 - Sonic tracking to guidance after 7 months
- Sonic operations
 - Pathology division performing well
 - Australian pathology division delivers excellent result
 - Margin pressure in radiology resolution underway
 - Notable record contribution from IPN
- Growth
 - Recent AEL acquisition in USA (January 2007)
 - Further Northern Hemisphere prospects in pipeline



2007 Full-Year Guidance

	2007 Guidance	
Organic Revenue Growth	Approximately 5%	
EPS Growth	Approximately 10%	

- Sonic 2007 guidance unchanged since 22 August 2006
- Sonic tracking to 2007 guidance after 7 months
- Includes CPL acquisition from 1 October 2005 and AEL acquisition from 8 January, 2007
- Assumes no additional acquisitions
- Assumes constant currency exchange rates




Revenue Growth

	6 Months ended	6 Months ended		
	31.12.06	31.12.05	Growth	
	(\$M)	(\$M)		
Total Revenue	881.3	788.7	11.7%	

- Total pathology revenue growth 16.4%
 - Includes CPL (acquired 1 October 2005)
 - Impacted by low growth rate of New Zealand market
 - Australian pathology revenue growth 7.4%
- Total imaging revenue growth 1.3%
 - Disposal of Hong Kong imaging business
 - Effects of MRI licence allocations
 - Competition from public hospitals
 - Rationalisation and restructure of Castlereagh Imaging





Earnings Growth

		6 Months ended	6 Months ended	Growth
		31.12.06	31.12.05	%
EBITA	(\$'000)	160,191	147,124	8.9%
EBITDA	(\$'000)	190,280	172,131	10.5%
NPAT	(\$'000)	93,528	83,195	12.4%
EPS	(cents)	31.2	29.0	7.6%
Cash Generation	(\$'000)	138,118	120,086	15.0%



2nd Half EPS Growth

- Typical strong second-half seasonality
- AEL acquisition
- Ongoing earnings improvement strategies
 - Global procurement
 - Benchmarking
 - IT strategies
- Australian pathology fee increases
 - DVA increase from 1 November 2006
 - Private fee increases in 2nd half 2006



Earnings Margins

	6 Months ended	6 Months ended	
	31.12.06	31.12.05	
EBITA Margin	18.2%	18.7%	
EBITDA Margin	21.6%	21.8%	

- Margin dilution due to
 - CPL acquisition CPL has lower margins than average of Sonic's other businesses
 - Imaging margins Low revenue growth and cost pressures associated with radiologists' remuneration restructuring
- EBITA margin expansion
 - Sonic group excluding CPL and Imaging up >50 basis points
 - Sonic pathology up >50 basis points
 - Australian pathology up >50 basis points




Interim Dividend

	2006	2005	Movement %
Interim Dividend	\$0.17	\$0.15	13%

- Dividend fully franked at 30%
- Record Date 14 March 2007
- Payment Date 28 March 2007
- Dividend Reinvestment Plan remains suspended



Debt / Capital Structure



- Debt at 31 December 2006 A\$812 million
- Plus acquisitions of AEL and CPL minorities A\$295 million
- Debt/EBITDA ratio ~2.7 (bank covenant <3.5)</p>
- Current headroom ~A\$250 million plus bridge facility
- Over A\$50 million equity "raised" in CPL minorities transaction



Australian Pathology

- Australian pathology division tracking strongly
- Margin expansion of >50 basis points over first half last year
- Douglass Hanly Moir Pathology (New South Wales)
 - Ongoing strong organic growth and margin expansion
 - Market share gains in New South Wales
- Sullivan Nicolaides Pathology (Queensland)
 - Solid performance with good cost control
- Clinipath (Western Australia)
 - Market share growth and margin expansion
- Melbourne Pathology (Victoria)
 - Ongoing strong revenue growth
- Sonic holds formidable position in Australian pathology market

New DHM Lab and Sonic Head Office

- Construction progressing smoothly
 - On budget and ahead of schedule
- New lab will allow for enhanced efficiencies
 - Centralisation of testing
 - New autolab significantly more efficient than current lab
- Relocation will take place in late 2007



New Zealand Pathology

- Market growth rates lower than Sonic's other laboratory markets
- Tenders / RFP's have dominated market over past year
- DML
 - Subject to Judicial Review outcome
- Medlab South
 - Sonic has gained revenue
 - Christchurch status quo to remain, two community players
 - Nelson Marlborough, new contract won
 - Otago-Southland, contract lost
- Valley Diagnostic
 - JV formed with Medlab Wellington to form new lab, Aotea Pathology
 - Sonic (45%) will not consolidate financials represents lost revenue
- Medlab Central
 - In progress, likely net gain of revenue



DML – Judicial Review

- Sonic/DML initiated legal action over loss of Auckland community laboratory contract to Labtests
- Hearing completed (12-23 February), outcome expected in weeks
- Sonic/DML position:
 - <u>RFP process flawed</u> Sonic priced contract to maintain current services (as mandated in RFP), Labtests bid to materially reduce service levels (halving of collection centres, reducing pathologists, extending turnaround times)
 - <u>Probity issues</u> Dr Tony Bierre, shareholder and CEO of Labtests, was a Board member of the DHB which awarded the contract to Labtests
 - <u>General Practitioners were not consulted</u> DHB's are legally obliged to consult with GP's about changes affecting primary care
- DML pathologists and staff united and resolute
- Financial impact of potential loss unclear
 - Appeals are possible
 - Sonic will keep market informed

SONIC HEALTHCARE

UK Pathology

- TDL continues to perform strongly
 - Solid revenue and earnings growth
 - Margin expansion
- UCLH joint venture robust and beneficial to both partners
- TDL wins Ealing pathology contract tender
 - Pathology provision for Ealing Hospital NHS Trust and Ealing Primary Care Trust
 - Multi-million pound contract over 5 years (commercial terms remain confidential)
 - First such contract since Lord Carter report on NHS pathology
 - Contract subject to documentation only
 - Ealing Trusts' press release posted on Sonic Healthcare website today
- Sonic/TDL progressing further outsourcing opportunities



European Pathology

- Steady performance from Schottdorf Group
 - Lower growth rates in German laboratory market
 - Provides excellent service for TDL esoteric tests
- Acquisition opportunities
 - Currently pursuing several transactions in Western Europe
 - German market fragmented, presents synergy potential with Schottdorf
 - Targeting acquisition and outsourcing opportunities
 - Expect significant rationalisation of market in next few years
- Plan to establish Sonic Europe management structure
 - Co-ordinate European operations
 - Drive synergies
 - Assist with acquisitions



US Pathology

- Sonic developing critical mass in US laboratory market
 - CPL acquisition in October 2005
 - AEL acquisition in January 2007
 - Annualised revenue approaching A\$400 million
 - Further acquisitions likely
- Sonic is the third-largest lab operator in the USA
- Sonic Healthcare model now widely recognised in USA market
 - Medical Leadership
 - Personalised service
 - "Federation" structure
 - Provides differentiation from competitors



CPL


- CPL performing consistently and to expectation
 - Organic growth rate around 8%
- Sonic acquisition of CPL minority shareholders
 - Decision driven by AEL acquisition
 - Allows synergy capture between Sonic entities without conflict issues
 - Averts the need for minorities to put up capital for acquisitions
 - Total consideration US\$82.7 million
 - US\$41.6 in cash, balance as ~4 million SHL shares (issued at A\$12.52, a 5% discount to price on 8 Dec '06)
- CPL provides outstanding platform for growth
 - Culture, values, model very similar to Sonic's
 - Strong management input into Sonic's US operations
 - Excellent integration at all levels with Sonic Australia



AEL

- Sonic acquisition of AEL completed in January 2007
- Purchase price US\$180 million
- AEL annual revenues ~A\$130 million
- AEL is a full-service laboratory operation
- Four main laboratory centres
 - Memphis, Tennessee (market leader)
 - Morristown, Tennessee
 - Tyler, Texas (CPL overlap)
 - Dallas, Texas (CPL overlap)
- Employs >700 staff
- AEL's strong growth to date ongoing
- Significant overlap and synergy potential with CPL





Sonic Healthcare USA, Inc.

- Sonic's US corporate entity
 - Based in Austin, Texas
 - Coordinate people and operations
 - Financial management
 - Drive growth, integration and synergy capture
 - Acquisitions
- Sonic's US operations
 - CPL and AEL are outstanding businesses
 - Further acquisitions in pipeline
- Sonic's US lab model presents clear differentiation
 - Medical Leadership
 - Personalised, regionalised services
 - "Federation" structure
- Outlook is for strong growth in US market



Imaging

- Revenue growth low
 - Rationalisation of Castlereagh Imaging
 - Public hospital competition
 - MRI licence allocations in Queensland in 2006
 - Sale of small, inherited Hong Kong business
- Margin contraction
 - EBITDA margin 22.2% (25.1% in prior year)
 - Low revenue growth
 - Cost pressure from Radiologists' remuneration restructure
- Outlook positive
 - Revenue turnaround and new markets in Queensland
 - New MRI licence in Townsville (from November 2006)
 - Restructure of Castlereagh business
 - Positive impact of incentive-based radiologists' remuneration plan
 - Productivity gains with roll-out of digital imaging applications
 Changes will flow through in 12-18 months

SONIC

CARE

IPN

IPN delivers outstanding half-year result

- Net profit up 63% to \$4.1 million
- Revenue from continuing operations up 6% to \$44.7 million
- Operating cash flow up 93% to \$6.1 million
- Earnings per share up 39% to \$0.39 per share
- IPN pursuing organic and acquisitional growth
- Sonic support for expansion (\$30 million debt facility)
- CEO Malcolm Parmenter providing strong medical leadership
- Outlook for continued strong growth



Future Growth

- Sonic's core laboratory businesses tracking strongly
 - Solid infrastructure in growing markets
 - Margin expansion from ongoing growth
- Imaging turnaround expected in near term
- Acquisition and outsourcing opportunities
 - USA laboratory market presents great potential for Sonic
 - European laboratory acquisition opportunities in pipeline
 - Laboratory outsourcing in UK and Europe

